ENDV stock jumps to $0.0001 on heavy volume PNK 13 Feb 2026: key signals to watch

ENDV stock opened the market on 13 Feb 2026 at $0.0001 on the PNK exchange in the United States after a sharp intraday rise. The price move represents a 9,900.00% change from the previous close of $0.000001 on very high activity, with reported volume at 999,999 shares. Traders are reacting to thin liquidity, micro-cap volatility, and company-level news flow that keeps short-term momentum intact while fundamentals remain fragile.

ENDV stock: today’s price action and liquidity

ENDV (Endonovo Therapeutics, Inc.) traded between $0.00005 and $0.0001 during market hours on 13 Feb 2026 on PNK in the United States. Volume hit 999,999 versus an average volume of 1,868,999, indicating heavy intraday interest but still limited free float. The market cap stands at $15,938.00 USD, reflecting micro-cap status and outsized volatility on small order flows.

Business snapshot and catalysts for ENDV trading

Endonovo Therapeutics, Inc. develops non-invasive Electroceutical devices such as SofPulse for regenerative medicine. The company is in the Healthcare sector, Biotechnology industry, and lists its site at Endonovo investor. Short operational updates or clinical development commentary often drive trading in ENDV stock because the underlying business is small and news-sensitive.

Financials and valuation metrics for Endonovo Therapeutics, Inc.

ENDV reports EPS -0.01 USD and a trailing P/E of -0.01, reflecting negative earnings. Key ratios show a book value per share of -0.025342 and a current ratio of 0.00065, signaling a weak balance sheet and scarce liquidity. Shares outstanding are 318,752,000, and the 50-day average price is $0.00009 versus the 200-day average of $0.00013.

Technical picture and short-term trading signals

Momentum indicators show RSI 51.20 and ADX 36.59, suggesting a measurable trend despite low-price noise. The 52-week range is $0.00005 to $0.0003, and on-chart averages show recent price compressions. Traders should note on-balance volume at 67,084,810 and the high days-payables metric, both consistent with micro-cap operational stress and irregular trading patterns.

Meyka AI grade and external analyst context

Meyka AI rates ENDV with a score of 66.26 out of 100 — Grade B, HOLD. This grade factors in S&P 500 benchmark comparison, sector and industry performance, financial growth, key metrics, and analyst consensus. External model data dated 2026-02-12 lists a company rating of C- / Strong Sell, highlighting divergence between our multi-factor grade and other screening signals.

Price targets, forecast and key risks for ENDV stock

Meyka AI’s forecast model projects $0.0000 over the next 12 months versus the current $0.0001 USD, implying an extreme downside in model output; forecasts are model-based projections and not guarantees. We present scenario price targets: bearish $0.00001, base $0.0001, bullish $0.0003 (near year high). Major risks include very low liquidity, negative EPS, weak current ratio, and concentrated shareholder structure. For raw data, see FinancialModelingPrep ENDV profile.

Final Thoughts

ENDV stock’s spike to $0.0001 USD on 13 Feb 2026 reflects micro-cap trading dynamics more than improved fundamentals. The company, Endonovo Therapeutics, Inc. (PNK), remains a small biotechnology issuer with EPS -0.01, negative book value, and a market cap of $15,938.00 USD, which keeps downside risk high. Our technical read shows short-term momentum (RSI 51.20, ADX 36.59), but liquidity and balance-sheet metrics argue for caution. Meyka AI’s multi-factor grade gives ENDV 66.26/100 (B, HOLD) while an external screener marks the stock C- / Strong Sell; this split indicates mixed signals between quantitative screening and short-term market action. Meyka AI’s forecast model projects $0.0000 USD, a model-based projection that implies significant downside versus the current price; forecasts are not guarantees. Traders seeking exposure should treat ENDV as speculative, size positions modestly, and monitor volume and company updates on the PNK exchange. For continued tracking, we provide live model updates on our Meyka AI-powered market analysis platform and maintain internal coverage at https://meyka.ai/stocks/ENDV

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.